GlobeNewswire·Aug 21, 2026, 8:30 AM ET

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

RNXT

RenovoRx, Inc. (NASDAQ: RNXT) received written confirmation from Nasdaq on August 20, 2026, that it has regained compliance with the minimum bid price requirement for continued listing.
The company met the Nasdaq Listing Rule 5550(a)(2) standard after its common stock closed at $1.00 or greater for 10 consecutive business days between August 6, 2026, and August 19, 2026.
The matter is now closed, with no effect on the trading of RenovoRx stock under the symbol "RNXT" on The Nasdaq Capital Market.
The company originally received a deficiency notice from Nasdaq on December 31, 2025.
CEO Shaun Bagai cited record second-quarter 2026 revenue, growth in active commercial cancer center customers for RenovoCath, and the first commercial clinical use of RenovoCath in a sarcoma patient as drivers of value.
RenovoRx completed enrollment in its Phase III TIGeR-PaC trial in August 2026, with trial completion expected in the first half of 2027 \& topline data readout expected in the second half of 2027.
RenovoCath is an FDA-cleared device for isolating blood flow \& delivering fluids to the peripheral vascular system, including temporary vessel occlusion for arteriography \& chemotherapeutic drug infusion.
In 2025, the company generated approximately $1.1 million in RenovoCath sales, followed by record quarterly revenue of $909,000 in Q2 2026.
The company is evaluating the IAG product candidate (intra-arterial gemcitabine delivered via RenovoCath) under an FDA investigational new drug application regulated by the 21 CFR 312 pathway.
IAG received Orphan Drug Designation for pancreatic cancer \& bile duct cancer, while oxaliplatin received Orphan Drug Designation for pancreatic cancer, each providing seven years of market exclusivity upon FDA approval.